The presence of drug-drug interactions (DDIs) did not increase the risk for colchicine-related gastrointestinal adverse events or impact the effectiveness of colchicine in ambulatory patients with COVID-19, according to a study conducted by Lama S. Alfehaid, PharmD. A total of 4432 patients were given colchicine or a placebo, with a small percentage having potential DDIs. The study found that DDIs did not influence the effect of colchicine on gastrointestinal adverse events, hospitalization, or mortality due to COVID-19. The study authors, Hemalkumar B. Mehta, PhD, and G. Caleb Alexander, MD, recommended testing potential DDIs identified through screening to prevent real-world harms.
Source link
Colchicine Drug Interactions May Not Affect Safety, Efficacy
